Higher temperatures linked to severity of allergic conjunctivitis

Article

Temperatures measured by a newly developed non-contact ocular surface thermographer (OST) can be used to evaluate the efficacy of topical anti-allergic agents because of the significant correlation of the conjunctival surface temperature and the severity of conjunctival allergic reaction, according to recently published data.

Temperatures measured by a newly developed non-contact ocular surface thermographer (OST) can be used to evaluate the efficacy of topical anti-allergic agents because of the significant correlation of the conjunctival surface temperature and the severity of conjunctival allergic reaction, according to the results of a study published in Ophthalmic Research.

Researchers from Ehime University School of Medicine included 13 asymptomatic patients with seasonal allergic conjunctivitis due to cedar pollen. They instilled a 0.025% levocabastine ophthalmic suspension in one eye and artificial tears in the other eye, in a masked fashion 10 minutes prior to a conjunctival allergen challenge (CAC). A drop of cedar pollen solution was then given into the conjunctival sac to induce an allergic reaction.

The surface temperature of the inferior bulbar conjunctiva was measured before and 30 minutes after CAC with a newly developed non-contact ocular surface thermographer (OST) Slit-lamp biomicroscopy was also used to measure the degree of conjunctival injection and chemosis. A questionnaire was used to evaluate symptoms.

After CAC, temperatures increased by 0.67 °C in the artificial tear eyes, and only by 0.21 °C in the levocabastine eyes (P P P

To access the abstract of this study, click here.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.